Xylem Cash & Equivalents decreased by 45.4% to $808.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 23.7%, from $1.06B to $808.00M. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows a downward trend with a -4.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher levels indicate strong liquidity and financial flexibility; lower levels may signal potential cash flow issues.
This represents the most liquid assets held by the company, including cash on hand, demand deposits, and short-term inve...
A universal metric for assessing a company's immediate financial health.
cash_and_equivalents| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.84B | $1.26B | $1.35B | $1.12B | $1.11B | $1.19B | $944.00M | $837.00M | $708.00M | $705.00M | $1.02B | $947.00M | $815.00M | $989.00M | $1.12B | $1.06B | $1.17B | $1.19B | $1.48B | $808.00M |
| QoQ Change | — | -31.8% | +7.5% | -17.2% | -0.4% | +6.6% | -20.4% | -11.3% | -15.4% | -0.4% | +44.5% | -7.1% | -13.9% | +21.3% | +13.3% | -5.5% | +10.5% | +1.8% | +24.2% | -45.4% |
| YoY Change | — | — | — | — | -39.5% | -5.5% | -30.0% | -25.1% | -36.4% | -40.6% | +7.9% | +13.1% | +15.1% | +40.3% | +10.0% | +11.8% | +43.6% | +20.4% | +31.9% | -23.7% |